Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
As at 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2022-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Name of reporting entity or other means of identification | — |
DBV Technologies SA
|
— |
| Legal form of entity | — |
SA
|
— |
| Country of incorporation | — |
France
|
— |
| Address of entity's registered office | — |
|
— |
| Description of nature of entity's operations and principal activities | — |
une société biopharmaceutique spécialisée, au stade clinique, qui vise à changer le domaine de l’immunothérapie en développant une nouvelle plateforme technologique appelée Viaskin®. L’approche thérapeutique de la Société repose sur l’immunothérapie épicutanée, ou EPIT™, une méthode exclusive pour administrer des composés biologiquement actifs au système immunitaire sur une peau intacte à l’aide de Viaskin®.
|
— |
| Statement of IFRS compliance [text block] | — |
En application du règlement européen n° 1606 / 2002 adopté le 19 juillet 2002 par le Parlement européen et le Conseil européen, les états financiers consolidés du Groupe de l’exercice 2023 sont établis en conformité avec le référentiel IFRS
|
— |
| Disclosure of uncertainties of entity's ability to continue as going concern [text block] | — |
◼
|
— |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current trade receivables |
-
USD
|
— |
-
USD
|
| Current trade payables |
23 302
USD
|
— |
14 473
USD
|
| Explanation of sources of estimation uncertainty with significant risk of causing material adjustment | — |
|
— |